POU2F3 (≥10% hotspot staining), CD117, and CD5 staining was seen in 51%, 86%, and 35% of carcinomas, respectively, and in none of the type A thymomas or micronodular thymomas with lymphoid stroma that were tested. This evidence concerns the gene CD5 and thymoma.